{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T21:59:05Z","timestamp":1769551145635,"version":"3.49.0"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2014,4,13]],"date-time":"2014-04-13T00:00:00Z","timestamp":1397347200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1007\/s00296-014-3006-2","type":"journal-article","created":{"date-parts":[[2014,4,12]],"date-time":"2014-04-12T05:33:09Z","timestamp":1397280789000},"page":"1345-1360","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Treatment of psoriatic arthritis with anti-TNF agents: a systematic review and meta-analysis of efficacy, effectiveness and safety"],"prefix":"10.1007","volume":"34","author":[{"given":"L\u00edvia Lovato Pires","family":"Lemos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juliana","family":"de Oliveira Costa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra Maciel","family":"Almeida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haliton Oliveira","family":"Junior","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariana Michel","family":"Barbosa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adriana Maria","family":"Kakehasi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco Assis","family":"Acurcio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,4,13]]},"reference":[{"issue":"5","key":"3006_CR1","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.jaad.2008.02.040","volume":"58","author":"A Gottlieb","year":"2008","unstructured":"Gottlieb A, Korman NJ, Gordon KB et al (2008) Guidelines of care for the management of psoriasis and psoriatic arthritis: section\u00a02. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol 58(5):851\u2013864","journal-title":"J Am Acad Dermatol"},{"issue":"suppl 2","key":"3006_CR2","doi-asserted-by":"crossref","first-page":"ii14","DOI":"10.1136\/ard.2004.032482","volume":"64","author":"DD Gladman","year":"2005","unstructured":"Gladman DD, Antoni C, Mease P et al (2005) Psoriatic arthritis: epidemiology, clinical features, course, and outcomes. Ann Rheum Dis 64(suppl 2):ii14\u2013ii17","journal-title":"Ann Rheum Dis"},{"key":"3006_CR3","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/1529-0131(200104)45:2<151::AID-ANR168>3.0.CO;2-T","volume":"45","author":"JA Husted","year":"2001","unstructured":"Husted JA, Gladman DD, Farewell VT, Cook RJ (2001) Health-related quality of life of patients with psoriatic arthritis: a comparison with patients with rheumatoid arthritis. Arthritis Care Res 45:151\u2013158","journal-title":"Arthritis Care Res"},{"key":"3006_CR4","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/1477-7525-7-25","volume":"7","author":"F Salaffi","year":"2009","unstructured":"Salaffi F, Carotti M, Gasparini S, Intorcia M, Grassi W (2009) The health-related quality of life in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis: a comparison with a selected sample of healthy people. Health Qual Life Outcomes 7:25. doi: 10.1186\/1477-7525-7-25","journal-title":"Health Qual Life Outcomes"},{"issue":"12","key":"3006_CR5","first-page":"680","volume":"35","author":"S Lee","year":"2010","unstructured":"Lee S, Mendelsohn A, Sarnes E (2010) The burden of psoriatic arthritis: a literature review from a global health systems perspective. J Clin Pharm Ther 35(12):680\u2013689","journal-title":"J Clin Pharm Ther"},{"key":"3006_CR6","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1093\/rheumatology\/ker365","volume":"51","author":"C Rosen","year":"2012","unstructured":"Rosen C, Mussani F, Chandran V, Eder L, Thavaneswaran A, Gladman D (2012) Patients with psoriatic arthritis have worse quality of life than those with psoriasis alone. Rheumatology 51:571\u2013576","journal-title":"Rheumatology"},{"key":"3006_CR7","first-page":"4","volume":"71","author":"L Gossec","year":"2012","unstructured":"Gossec L, Smolen J, Gaujoux-Viala CL et al (2012) European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Arthritis Rheum 71:4\u201312","journal-title":"Arthritis Rheum"},{"issue":"2","key":"3006_CR8","first-page":"282","volume":"30","author":"C Pereda","year":"2012","unstructured":"Pereda C, Nishishinya M, Martinez Lopez J, Carmona L (2012) Efficacy and safety of DMARDs in psoriatic arthritis: a systematic review. Clin Exp Rheumatol 30(2):282\u2013289","journal-title":"Clin Exp Rheumatol"},{"key":"3006_CR9","unstructured":"Higgins JPT, Green S (eds) (2011) Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011]. The Cochrane collaboration. www.cochrane-handbook.org"},{"key":"3006_CR10","doi-asserted-by":"crossref","first-page":"b2700","DOI":"10.1136\/bmj.b2700","volume":"339","author":"A Liberati","year":"2009","unstructured":"Liberati A, Altman DG, Tetzlaff J et al (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. Brit Med J 339:b2700","journal-title":"Brit Med J"},{"issue":"6","key":"3006_CR11","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/art.1780380602","volume":"38","author":"DT Felson","year":"1995","unstructured":"Felson DT, Anderson JJ, Boers M et al (1995) American-College-of-Rheumatology preliminary definition of improvement in rheumatoid-arthritis. Arthritis Rheum 38(6):727\u2013735","journal-title":"Arthritis Rheum"},{"key":"3006_CR12","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1002\/art.1780391210","volume":"39","author":"DO Clegg","year":"1966","unstructured":"Clegg DO, Reda DJ, Mejias E et al (1966) Comparision of sulfassalazine and placebo in the treatment of psoriatic arthritis: a Department of Veterans Affairs cooperative study. Arthritis Rheum 39:2013\u20132020","journal-title":"Arthritis Rheum"},{"issue":"Suppl. 39","key":"3006_CR13","first-page":"S93","volume":"23","author":"J Fransen","year":"2005","unstructured":"Fransen J, van Riel PLCM (2005) The disease activity score and the EULAR response criteria. ClinExpRheumatol 23(Suppl. 39):S93\u2013S99","journal-title":"ClinExpRheumatol"},{"key":"3006_CR14","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1159\/000250839","volume":"157","author":"T Fredriksson","year":"1978","unstructured":"Fredriksson T, Pettersson U (1978) Severe psoriasis oral therapy with a new retinoid. Dermatologica 157:238\u2013244","journal-title":"Dermatologica"},{"key":"3006_CR15","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1136\/ard.49.11.916","volume":"49","author":"DMFM Heijde Van der","year":"1990","unstructured":"Van der Heijde DMFM, van\u2018t Hof MA, van Riel PLCM et al (1990) Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score. Ann Rheum Dis 49:916\u2013920","journal-title":"Ann Rheum Dis"},{"key":"3006_CR16","first-page":"789","volume":"9","author":"JF Fries","year":"1982","unstructured":"Fries JF, Spitz PW, Young DY (1982) The dimensions of health outcomes: the Health Assessment Questionnaire, disability and pain scales. J Rheumatol 9:789\u2013793","journal-title":"J Rheumatol"},{"key":"3006_CR17","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","volume":"30","author":"JE Ware","year":"1992","unstructured":"Ware JE, Sherbourne CD (1992) The MOS 36-item short-form health survey: I. Conceptual framework and item selection. Med Care 30:473\u2013483","journal-title":"Med Care"},{"key":"3006_CR18","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/00005650-199303000-00006","volume":"31","author":"CA McHorney","year":"1993","unstructured":"McHorney CA, Ware JE Jr, Raczek AE (1993) The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care 31:247\u2013263","journal-title":"Med Care"},{"key":"3006_CR19","first-page":"232","volume":"11","author":"D Cella","year":"1997","unstructured":"Cella D, Webster K (1997) Linking outcomes management to quality-of-life measurement. Oncology 11:232\u2013235","journal-title":"Oncology"},{"issue":"1","key":"3006_CR20","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/j.1524-4733.2007.00213.x","volume":"11","author":"JA Cramer","year":"2008","unstructured":"Cramer JA, Roy A, Burrell A et al (2008) Medication compliance and persistence:terminology and definitions. Value Health 11(1):44\u201347","journal-title":"Value Health"},{"issue":"21","key":"3006_CR21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta9210","volume":"9","author":"R Woodroffe","year":"2005","unstructured":"Woodroffe R, Yao GL, Meads C et al (2005) Clinical and cost-effectiveness of newer immunosuppressive regimens in renal transplantation: a systematic review and modelling study. Health Technol Asses 9(21):1\u2013179 (iii\u2013iv)","journal-title":"Health Technol Asses"},{"key":"3006_CR22","unstructured":"Higgins JPT, Altman AD, Sterne JAC (2012) Chapter 8: assessing risk of bias in included studies. In: Higgins JPT, Altman DG, Sterne JAC (eds) Cochrane handbook for systematic reviews of interventions. Version 5.1.0 [updated March 2011]. www.cochrane-handbook.org"},{"key":"3006_CR23","unstructured":"Hartling L, Hamm M, Milne A et al (2012) Validity and inter-rater reliability testing of quality assessment instruments [internet]. Appendix E, decision rules for application of the Newcastle-Ottawa Scale. Agency for Healthcare Research and Quality (US), Rockville (MD). http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK92291\/"},{"issue":"1","key":"3006_CR24","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2307\/2529310","volume":"33","author":"JR Landis","year":"1997","unstructured":"Landis JR, Koch GG (1997) The measurement of observer agreement for categorical data. Biometrics 33(1):159\u2013174","journal-title":"Biometrics"},{"key":"3006_CR25","unstructured":"Deeks JJ, Higgins J, Altman DG (2012) Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (eds) Cochrane handbook for systematic reviews of interventions. Version 5.1.0 [updated March 2011]. www.cochrane-handbook.org"},{"key":"3006_CR26","doi-asserted-by":"crossref","first-page":"R52","DOI":"10.1186\/ar2670","volume":"11","author":"AA Saad","year":"2009","unstructured":"Saad AA, Ashcroft DM, Watson KD, Hyrich KL, Noyce PR, Symmons DPM (2009) Persistence with anti-tumour necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics Register. Arthritis Res Ther 11:R52. doi: 10.1186\/ar2670","journal-title":"Arthritis Res Ther"},{"key":"3006_CR27","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1093\/rheumatology\/kep423","volume":"49","author":"AA Saad","year":"2010","unstructured":"Saad AA, Ashcroft DM, Watson KD et al (2010) Efficacy and safety of anti-TNF therapies in psoriatic arthritis: an observational study from the British Society for Rheumatology Biologics Register. Rheumatology 49:697\u2013705","journal-title":"Rheumatology"},{"issue":"3","key":"3006_CR28","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1002\/acr.20104","volume":"62","author":"AA Saad","year":"2010","unstructured":"Saad AA, Ashcroft DM, Watson KD et al (2010) Improvements in quality of life and functional status in patients with psoriatic arthritis receiving anti-tumor necrosis factor therapies. Arthrit Care Res 62(3):345\u2013353","journal-title":"Arthrit Care Res"},{"key":"3006_CR29","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.3899\/jrheum.091477","volume":"37","author":"LM Virkki","year":"2010","unstructured":"Virkki LM, Sumathikutty BC, Arnio MA et al (2010) Biological therapy for psoriatic arthritis in clinical practice: outcomes up to 2 years. J Rheumatol 37:2362\u20132368","journal-title":"J Rheumatol"},{"key":"3006_CR30","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.semarthrit.2010.07.004","volume":"40","author":"I Saougou","year":"2011","unstructured":"Saougou I, Markatseli TE, Papagoras C et al (2011) Sustained clinical response in psoriatic arthritis patients treated with anti-TNF agents: a 5-year open-label observational cohort study. Semin Arthritis Rheum 40:398\u2013406","journal-title":"Semin Arthritis Rheum"},{"issue":"4","key":"3006_CR31","first-page":"206","volume":"66","author":"B Chastek","year":"2012","unstructured":"Chastek B, Prairie E, Watson C et al (2012) Tumor necrosis factor-blocker therapy persistence, gaps, and switching among patients with psoriatic arthritis. J Am Acad Dermatol 66(4):206 (Suppl 1)","journal-title":"J Am Acad Dermatol"},{"key":"3006_CR32","doi-asserted-by":"crossref","first-page":"369","DOI":"10.3109\/09546634.2012.755255","volume":"24","author":"M Bonafede","year":"2013","unstructured":"Bonafede M, Johnson BH, Fox KM, Watson C, Gandra SR (2013) Treatment patterns with etanercept and adalimumab for psoriatic diseases in a real-world setting. J Dermatolog Treat 24:369\u2013373","journal-title":"J Dermatolog Treat"},{"issue":"10","key":"3006_CR33","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1002\/art.21306","volume":"52","author":"P Mease","year":"2005","unstructured":"Mease P, Gladman D, Ritchlin C et al (2005) Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis. Arthritis Rheum 52(10):3279\u20133289","journal-title":"Arthritis Rheum"},{"key":"3006_CR34","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1136\/ard.2006.057901","volume":"66","author":"D Gladman","year":"2007","unstructured":"Gladman D, Mease P, Cifaldi M, Perdok R, Sasso E, Medich J (2007) Adalimumab improves joint-related and skin-related functional impairment in patients with psoriatic arthritis: patient-reported outcomes of the Adalimumab Effectiveness in Psoriatic Arthritis Trial. Ann Rheum Dis 66:163\u2013168","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"3006_CR35","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1002\/art.22379","volume":"56","author":"D Gladman","year":"2007","unstructured":"Gladman D, Mease P, Ritchlin C et al (2007) Adalimumab for long-term treatment of psoriatic arthritis. Arthritis Rheum 56(2):476\u2013488","journal-title":"Arthritis Rheum"},{"key":"3006_CR36","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1136\/ard.2008.092767","volume":"68","author":"P Mease","year":"2009","unstructured":"Mease P, Ory P, Sharp J et al (2009) Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT). Ann Rheum Dis 68:702\u2013709","journal-title":"Ann Rheum Dis"},{"key":"3006_CR37","first-page":"1","volume":"34","author":"M Genovese","year":"2007","unstructured":"Genovese M, Mease P, Thomason G et al (2007) Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy. J Rheumatol 34:1\u20135","journal-title":"J Rheumatol"},{"key":"3006_CR38","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0140-6736(00)02530-7","volume":"356","author":"P Mease","year":"2000","unstructured":"Mease P, Goffe B, Metz J, Vanderstoep A, Finck B, Burge D (2000) Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 356:385\u2013390","journal-title":"Lancet"},{"issue":"7","key":"3006_CR39","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1002\/art.20335","volume":"50","author":"P Mease","year":"2004","unstructured":"Mease P, Kivitz A, Burch F et al (2004) Etanercept treatment of psoriatic arthritis. Arthritis Rheum 50(7):2264\u20132272","journal-title":"Arthritis Rheum"},{"issue":"4","key":"3006_CR40","first-page":"712","volume":"33","author":"P Mease","year":"2006","unstructured":"Mease P, Kivitz A, Burch F et al (2006) Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2\u00a0years of treatment with etanercept. J Rheumatol 33(4):712\u2013721","journal-title":"J Rheumatol"},{"issue":"6","key":"3006_CR41","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.3899\/jrheum.091093","volume":"37","author":"P Mease","year":"2010","unstructured":"Mease P, Woolley M, Singh A, Tsuji W, Dunn M, Chou C-F (2010) Patient-reported outcomes in a randomized trial of etanercept in psoriatic arthritis. J Rheumatol 37(6):1221\u20131227","journal-title":"J Rheumatol"},{"issue":"4","key":"3006_CR42","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1002\/art.24403","volume":"60","author":"A Kavanaugh","year":"2009","unstructured":"Kavanaugh A, Mcinnes I, Mease P et al (2009) Golimumab, a new human tumor necrosis factor \u03b1 antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis. Arthritis Rheum 60(4):976\u2013986","journal-title":"Arthritis Rheum"},{"issue":"8","key":"3006_CR43","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1002\/art.34436","volume":"64","author":"A Kavanaugh","year":"2012","unstructured":"Kavanaugh A, Van Der Heijde D, Mcinnes I et al (2012) Golimumab in psoriatic arthritis. Arthritis Rheum 64(8):2504\u20132517","journal-title":"Arthritis Rheum"},{"key":"3006_CR44","first-page":"1","volume":"0","author":"A Kavanaugh","year":"2012","unstructured":"Kavanaugh A, Mcinnes I, Mease P et al (2012) Clinical efficacy, radiographic and safety findings through 2\u00a0years of golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of the randomized, placebo-controlled GO-REVEAL study. Ann Rheum Dis 0:1\u201310","journal-title":"Ann Rheum Dis"},{"issue":"suppl. 89","key":"3006_CR45","first-page":"90","volume":"39","author":"A Kavanaugh","year":"2012","unstructured":"Kavanaugh A, Mease P (2012) Treatment of psoriatic arthritis with tumor necrosis factor inhibitors: longer-term outcomes including enthesitis and dactylitis with golimumab treatment in the longterm extension of a randomized, placebo-controlled study. J Rheumatol 39(suppl. 89):90\u201393","journal-title":"J Rheumatol"},{"issue":"10","key":"3006_CR46","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1002\/acr.22044","volume":"65","author":"A Kavanaugh","year":"2013","unstructured":"Kavanaugh A, McInnes IB, Krueger GG et al (2013) Patient-reported outcomes and the association with clinical response in patients with active psoriatic arthritis treated with golimumab: findings through 2 years of a phase III, multicenter, randomized, double-blind, placebo-controlled trial. Arthrit Care Res 65(10):1666\u20131673","journal-title":"Arthrit Care Res"},{"issue":"4","key":"3006_CR47","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1002\/art.20967","volume":"52","author":"C Antoni","year":"2005","unstructured":"Antoni C, Kavanaugh A, Kirkham B et al (2005) Sustained benefits of infliximab theray for dermatologic and articular manifestations of psoriatic arthritis. Arthritis Rheum 52(4):1227\u20131236","journal-title":"Arthritis Rheum"},{"key":"3006_CR48","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1136\/ard.2005.045658","volume":"65","author":"A Kavanaugh","year":"2006","unstructured":"Kavanaugh A, Antoni C, Gladman D et al (2006) The infliximab multinational psoriatic arthritis controlled trial (IMPACT): results of radiographic analyses after 1\u00a0year. Ann Rheum Dis 65:1038\u20131043","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"3006_CR49","first-page":"869","volume":"35","author":"C Antoni","year":"2008","unstructured":"Antoni C, Kavanaugh A, van der Heijde D et al (2008) Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: findings of the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT). J Rheumatol 35(5):869\u2013876","journal-title":"J Rheumatol"},{"key":"3006_CR50","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1136\/ard.2004.032268","volume":"64","author":"C Antoni","year":"2005","unstructured":"Antoni C, Krueger G, Vlam K et al (2005) Inflixmab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis 64:1150\u20131157","journal-title":"Ann Rheum Dis"},{"key":"3006_CR51","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1136\/ard.2005.040196","volume":"65","author":"A Kavanaugh","year":"2006","unstructured":"Kavanaugh A, Antoni C, Krueger G, Yan S, Bala M, Dooley L, Beautler A, Guzza C, Gladman D (2006) Infliximab improves health related quality of life and physical function in patients with psoriatic arthritis. Ann Rheum Dis 65:471\u2013477","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"3006_CR52","first-page":"2254","volume":"33","author":"A Kavabaungh","year":"2006","unstructured":"Kavabaungh A, Anatoni C, Mease P, Gladman D, Yan S, Bala M, Dooley L, Beutler A, GuzzoU C, Krueger G (2006) Effect of infliximab therapy on employment, time lost from work, and productivity in patients with psoriatic arthritis. J Rheumatol 33(11):2254\u20132259","journal-title":"J Rheumatol"},{"issue":"8","key":"3006_CR53","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1002\/art.22805","volume":"56","author":"D Heijde van der","year":"2007","unstructured":"van der Heijde D, Kavanaugh A, Gladman D et al (2007) Infliximab inhibits progression of radiographic damage in patients with active psoriatic arthritis through one year of treatment. Arthritis Rheum 56(8):2698\u20132707","journal-title":"Arthritis Rheum"},{"key":"3006_CR54","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1136\/ard.2006.058339","volume":"66","author":"A Kavanaugh","year":"2007","unstructured":"Kavanaugh A, Krueger G, Beutler A et al (2007) Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1\u00a0year of treatment: results from the IMPACT 2 trial. Ann Rheum Dis 66:498\u2013505","journal-title":"Ann Rheum Dis"},{"key":"3006_CR55","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1136\/ard.2011.152223","volume":"71","author":"A Baranauskaite","year":"2012","unstructured":"Baranauskaite A, Raffayav\u00e1 H, Kungurov N et al (2012) Infliximab plus methotrexate is superior to methotrexate alone in the treatment of psoriatic arthritis in methotrexate-naive patients: the RESPOND study. Ann Rheum Dis 71:541\u2013548","journal-title":"Ann Rheum Dis"},{"key":"3006_CR56","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s10067-009-1340-7","volume":"29","author":"M Atteno","year":"2010","unstructured":"Atteno M, Peluso R, Costa L, Padula S, Caso F, Iervolino S, Sanduzzi A, Lubrano E, Del Puente A, Scarpa R (2010) Comparison of effectiveness and safety of infliximab, etanercept, and adalimumab in psoriatic arthritis patients who experienced an inadequate response to previous disease-modifying antirheumatic drugs. Clin Rheumatol 29:399\u2013403","journal-title":"Clin Rheumatol"},{"issue":"8","key":"3006_CR57","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1002\/art.21972","volume":"54","author":"W Taylor","year":"2006","unstructured":"Taylor W, Gladman D, Helliwell P et al (2006) Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 54(8):2665\u20132673","journal-title":"Arthritis Rheum"},{"key":"3006_CR58","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1002\/art.1780341003","volume":"34","author":"M Dougados","year":"1991","unstructured":"Dougados M, van der Linden S, Juhlin R et al (1991) The European Spondyloarthropathy Study Group preliminary criteria for the classification of spondyloarthropathy. Arthritis Rheum 34:1218\u20131227","journal-title":"Arthritis Rheum"},{"key":"3006_CR59","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1136\/ard.2007.072652","volume":"67","author":"V Ravindran","year":"2008","unstructured":"Ravindran V, Scott DL, Choy EH (2008) A systematic review and meta-analysis of efficacy and toxicity of disease modifying anti-rheumatic drugs and biological agents for psoriatic arthritis. Ann Rheum Dis 67:855\u2013859","journal-title":"Ann Rheum Dis"},{"key":"3006_CR60","first-page":"883","volume":"35","author":"AA Saad","year":"2008","unstructured":"Saad AA, Symmons DP, Noyce PR et al (2008) Risks and benefits of tumor necrosis factor-alpha inhibitors in the management of psoriatic arthritis: systematic review and metaanalysis of randomized controlled trials. J Rheumatol 35:883\u2013890","journal-title":"J Rheumatol"},{"key":"3006_CR61","first-page":"587","volume":"24","author":"NF Woolacott","year":"2006","unstructured":"Woolacott NF, Khadjesari ZC, Bruce IN et al (2006) Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review. Clin Exp Rheumatol 24:587\u2013593","journal-title":"Clin Exp Rheumatol"},{"key":"3006_CR62","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1136\/ard.2011.150995","volume":"71","author":"Z Ash","year":"2012","unstructured":"Ash Z, Gaujoux-Viala C, Gossec L (2012) A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis. Ann Rheum Dis 71:319\u2013326","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"3006_CR63","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1002\/art.22353","volume":"55","author":"A Finckh","year":"2006","unstructured":"Finckh A, Liang MH, Mugica C (2006) Long-term impact of early treatment on radiographic progression in rheumatoid arthritis: a meta-analysis. Arthritis Rheum 55(6):864\u2013872","journal-title":"Arthritis Rheum"},{"key":"3006_CR64","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/1471-2474-14-101","volume":"14","author":"LC Coates","year":"2013","unstructured":"Coates LC, Navarro-Coy N, Brown SR et al (2013) The TICOPA protocol (TIght COntrol of Psoriatic Arthritis): a randomised controlled trial to compare intensive management versus standard care in early psoriatic arthritis. BMC Musculoskelet Disord 14:101. doi: 10.1186\/1471-2474-14-101","journal-title":"BMC Musculoskelet Disord"},{"issue":"10, supplement","key":"3006_CR65","first-page":"S346","volume":"65","author":"LC Coates","year":"2013","unstructured":"Coates LC, Moverley AR, McParland L et al (2013) Results of a randomised controlled trial comparing tight control of early psoriatic arthritis (TICOPA) with standard care: tight control improves outcome. Arthritis Rheum 65(10, supplement):S346","journal-title":"Arthritis Rheum"},{"key":"3006_CR66","unstructured":"NICE (2011) NICE technology appraisal guidance 220 Golimumab for the treatment of psoriatic arthritis. www.nice.org.uk\/guidance\/TA220"},{"key":"3006_CR67","unstructured":"NICE (2013) NICE technology appraisal guidance 199. Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis (review of technology appraisal guidance 104 and 125). www.nice.org.uk\/guidance\/TA199"},{"issue":"6","key":"3006_CR68","doi-asserted-by":"crossref","first-page":"e184","DOI":"10.1371\/journal.pmed.0040184","volume":"4","author":"L Bero","year":"2007","unstructured":"Bero L, Oostvogel F, Bacchetti P, Lee K (2007) Factors associated with findings of published trials of drug\u2013drug comparisons: why some statins appear more efficacious than others. PLoS Med 4(6):e184. doi: 10.1371\/journal.pmed.0040184","journal-title":"PLoS Med"},{"key":"3006_CR69","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1136\/bmj.326.7400.1167","volume":"326","author":"J Lexchin","year":"2003","unstructured":"Lexchin J, Bero LA, Djulbegovic B, Clark O (2003) Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ 326:1167. doi: 10.1136\/bmj.326.7400.1167","journal-title":"BMJ"},{"key":"3006_CR70","first-page":"977","volume":"27","author":"E Lubrano","year":"2009","unstructured":"Lubrano E, Marchesoni A, Olivieri I et al (2009) The radiological assessment of axial involvement in psoriatic arthritis: a validation study of the BASRI total and the modified SASSS scoring methods. Clin Exp Rheumatol 27:977\u2013980","journal-title":"Clin Exp Rheumatol"},{"key":"3006_CR71","doi-asserted-by":"crossref","unstructured":"Coates L, Tillett W, Chandler D (2012) The 2012 BSR and BHPR guideline for the treatment of psoriatic arthritis with biologics. Rheumatology first published online 25 July 2013. doi: 10.1093\/rheumatology\/ket187","DOI":"10.1093\/rheumatology\/ket187"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-014-3006-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00296-014-3006-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-014-3006-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T10:30:46Z","timestamp":1746181846000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00296-014-3006-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4,13]]},"references-count":71,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["3006"],"URL":"https:\/\/doi.org\/10.1007\/s00296-014-3006-2","relation":{},"ISSN":["0172-8172","1437-160X"],"issn-type":[{"value":"0172-8172","type":"print"},{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,4,13]]}}}